Cell Therapy in HFpEF

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2022

Study Completion Date

March 31, 2022

Conditions
Heart Failure With Normal Ejection Fraction
Interventions
BIOLOGICAL

Cell Therapy

Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.

Trial Locations (1)

1000

University Medical Center Ljubljana, Ljubljana

All Listed Sponsors
lead

University Medical Centre Ljubljana

OTHER

NCT02923609 - Cell Therapy in HFpEF | Biotech Hunter | Biotech Hunter